Avelumab Demonstrates Efficacy Across All Subgroups in Metastatic Merkel Cell Carcinoma

Best Practices in Immunotherapy – June/July 2017 Vol 8

For patients with metastatic Merkel cell carcinoma, a rare and aggressive form of skin cancer associated with poor survival, avelumab may soon offer a new therapeutic option.

According to subgroup analysis of efficacy presented at the 2017 ASCO- SITC Clinical Immuno-Oncology Symposium, avelumab monotherapy showed durable antitumor activity across all evaluable subgroups of patients with chemotherapy-refractory metastatic Merkel cell carcinoma.

No predictive biomarker with clear clinical utility was identified, but there was a trend of higher response in patients with PD-L1_positive versus PD-L1_negative tumors, the researchers reported.

Last modified: November 5, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code